PUBLICATIONS AND PresentationS

The treatment of COVID-19 patients, especially in severe conditions, presents a challenge to medical professionals. Plasma from recovered COVID-19 patients is a potential and promising therapeutic option, and efforts are underway at different levels to encourage convalescent plasma donations [1, 2].

PDMPs constitute several classes of biologic therapies, i.e. clotting factors, immunoglobulins (IgGs, including hyperimmune globulins), alpha-1 proteinase inhibitors, albumin and C1-esterase inhibitors. PDMPs share a unique nature: they are derived from human biologic material (plasma) and have a highly complex and regulated manufacturing process.

Whole blood and red blood cell (RBC) donors are at risk of iron deficiency. Since Source plasma (SP) donors have RBCs returned during apheresis, risk of iron depletion appears low. However, SP donors can donate frequently and assessment of frequent donor iron status is needed.

Plasma protein therapies (PPTs) are biologic medicines that provide critical health benefits, especially for patients with plasma protein deficiencies. Plasma protein deficiencies are a group of chronic, serious, and mostly rare conditions that occur when a person has deficient or functionally damaged proteins in plasma—the liquid portion of blood.